^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    hV01

    i
    Other names: hV01, CVD-1301.V01
    Associations

    News

    Trials
    Company:
    ConVerd
    Drug class:
    Immunomodulator, IL-21 agonist
    Related drugs:
    Associations

    News

    Trials
    1m
    A study to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21 oncolytic vaccinia virus injection (hV01) and ready-to-use CAR-raNK cells (IBR854) in patients with advanced malignant solid tumors (ChiCTR2500109506)
    P=N/A, N=5, Completed, Xiamen Humanity Hospital; Xiamen Humanity Hospital
    New trial
    |
    IBR854 • hV01
    2ms
    A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors. (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Hangzhou Converd Co., Ltd.
    New trial
    |
    Tevimbra (tislelizumab-jsgr) • hV01
    3ms
    Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Hangzhou Converd Co., Ltd. | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Oct 2025
    Enrollment closed • Trial primary completion date
    |
    hV01
    4ms
    Combination therapy of oncolytic vaccinia virus and PD-1 inhibitor in advanced solid tumors (ChiCTR2500103773)
    P=N/A, N=24, Not yet recruiting, Xiamen Humanity Hospital; Xiamen Humanity Hospital
    New trial
    |
    hV01
    7ms
    Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, Hangzhou Converd Co., Ltd. | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial primary completion date
    |
    hV01
    over2years
    Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection（hV01) in Advanced Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, Hangzhou Converd Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Oncolytic virus • Metastases
    |
    IL21 (Interleukin 21)
    |
    hV01
    over2years
    Safety of Recombinant Human IL-21 Oncolytic Vaccinia Virus Injection（hV01) in Advanced Tumors (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Hangzhou Converd Co., Ltd.
    New P1 trial • Oncolytic virus • Metastases
    |
    IL21 (Interleukin 21)
    |
    hV01